Vertex Pharmaceuticals misses analyst estimates on the top and bottom lines in the first quarter. Vertex raises its full-year 2025 revenue guidance to a range of $11.85 billion to $12 billion ...

Amid the launch of its non-opioid pain med Journavx, Vertex Pharmaceuticals has begun an awareness-raising blitz focused on acute pain management. The new campaign stars former NFL quarterback ...

Mathematicians love the certainty of proofs. This is how they verify that their intuition matches observable truth.

Good day, and welcome to the Vertex Pharmaceuticals First Quarter 2025 Earnings Call. [Operator Instructions]. Please note this event is being recorded. I would now like to turn the conference ...

Investing.com -- Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported first-quarter results that fell short of analyst expectations, sending shares down 2.8% in after-hours trading on Monday.

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

Vertex Pharma has teamed up with Orum Therapeutics to develop a conditioning regimen, used to prepare patients to receive gene-editing medicines, that it hopes will offer a more tolerable ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...